# A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

> **NCT03971071** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 620 (actual)

## Conditions studied

- Migraine Headache

## Interventions

- **DRUG:** Erenumab 70 mg
- **DRUG:** Erenumab 140 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03971071
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-07
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-06-13
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971071, "A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03971071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*